Major Histocompatibility Complex Class II+B7-1+ Tumor Cells Are Potent Vaccines for Stimulating Tumor Rejection in Tumor-bearing Mice

Overview

Journal J Exp Med

Specialties Allergy & Immunology
General Medicine

Date 1995 Feb 1

PMID 7836917

Citations 43

Authors

S Baskar

L Glimcher

N Nabavi

R T Jones

S Ostrand-Rosenberg

Affiliations

Soon will be listed here.

Abstract

Mice carrying large established major histocompatibility complex (MHC) class 1+ sarcoma tumors can be successfully treated by immunization with genetically engineered sarcoma cells transfected with syngeneic MHC class II plus B7-1 genes. This approach is significantly more effective than previously described strategies using cytokine- or B7-transduced tumor cells which are only effective against smaller tumor loads, and which cannot mediate regression of longer-term established tumors. The most efficient tumor rejection occurs if both the class II and B7-1 molecules are coexpressed on the same tumor cell. Immunity induced by immunization with class II+B7-1(+)-transfected sarcoma cells involves CD4+ and CD8+ T cells, suggesting that the increased effectiveness of the transfectants is due to their ability to activate both of these T cell populations.

Citing Articles

Antibodies Targeting Human or Mouse VSIG4 Repolarize Tumor-Associated Macrophages Providing the Potential of Potent and Specific Clinical Anti-Tumor Response Induced across Multiple Cancer Types.

Sazinsky S, Zafari M, Klebanov B, Ritter J, Nguyen P, Phennicie R Int J Mol Sci. 2024; 25(11).

PMID: 38892347 PMC: 11172757. DOI: 10.3390/ijms25116160.

Potentiating tumor immunity using aptamer-targeted RNAi to render CD8 T cells resistant to TGFβ inhibition.

Puplampu-Dove Y, Gefen T, Rajagopalan A, Muheramagic D, Schrand B, Gilboa E Oncoimmunology. 2018; 7(4):e1349588.

PMID: 29632714 PMC: 5889204. DOI: 10.1080/2162402X.2017.1349588.

Aptamer-Targeted Attenuation of IL-2 Signaling in CD8 T Cells Enhances Antitumor Immunity.

Rajagopalan A, Berezhnoy A, Schrand B, Puplampu-Dove Y, Gilboa E Mol Ther. 2017; 25(1):54-61.

PMID: 28129128 PMC: 5363184. DOI: 10.1016/j.ymthe.2016.10.021.

Plasma membrane vesicles decorated with glycolipid-anchored antigens and adjuvants via protein transfer as an antigen delivery platform for inhibition of tumor growth.

Patel J, Vartabedian V, Bozeman E, Caoyonan B, Srivatsan S, Pack C Biomaterials. 2015; 74:231-44.

PMID: 26461116 PMC: 4661141. DOI: 10.1016/j.biomaterials.2015.09.031.

Polymerase ε (POLE) ultra-mutated tumors induce robust tumor-specific CD4+ T cell responses in endometrial cancer patients.

Bellone S, Centritto F, Black J, Schwab C, English D, Cocco E Gynecol Oncol. 2015; 138(1):11-7.

PMID: 25931171 PMC: 4469551. DOI: 10.1016/j.ygyno.2015.04.027.

References

Chen P, Ananthaswamy H . Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2. J Immunol. 1993; 151(1):244-55. View

Baskar S, Ostrand-Rosenberg S, Nabavi N, Nadler L, Freeman G, Glimcher L . Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc Natl Acad Sci U S A. 1993; 90(12):5687-90. PMC: 46786. DOI: 10.1073/pnas.90.12.5687. View

Clements V, Ostrand-Rosenberg S . Beta 2M-/- knockout mice contain low levels of CD8+ cytotoxic T lymphocyte that mediate specific tumor rejection. J Immunol. 1993; 151(11):6283-90. View

Tahara H, Zeh 3rd H, Storkus W, Pappo I, Watkins S, Gubler U . Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res. 1994; 54(1):182-9. View

Chen L, McGowan P, Ashe S, Johnston J, Li Y, Hellstrom I . Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med. 1994; 179(2):523-32. PMC: 2191382. DOI: 10.1084/jem.179.2.523. View

Apasov S, Sitkovsky M . Development and antigen specificity of CD8+ cytotoxic T lymphocytes in beta 2-microglobulin-negative, MHC class I-deficient mice in response to immunization with tumor cells. J Immunol. 1994; 152(5):2087-97. View

Baskar S, Azarenko V, Garcia Marshall E, Hughes E, Ostrand-Rosenberg S . MHC class II-transfected tumor cells induce long-term tumor-specific immunity in autologous mice. Cell Immunol. 1994; 155(1):123-33. DOI: 10.1006/cimm.1994.1106. View

Li Y, McGowan P, Hellstrom I, Hellstrom K, Chen L . Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. J Immunol. 1994; 153(1):421-8. View

Oi V, Jones P, Goding J, Herzenberg L . Properties of monoclonal antibodies to mouse Ig allotypes, H-2, and Ia antigens. Curr Top Microbiol Immunol. 1978; 81:115-20. DOI: 10.1007/978-3-642-67448-8_18. View

10.

Sarmiento M, Glasebrook A, Fitch F . IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt 2 antigen block T cell-mediated cytolysis in the absence of complement. J Immunol. 1980; 125(6):2665-72. View

11.

Ozato K, Sachs D . Monoclonal antibodies to mouse MHC antigens. III. Hybridoma antibodies reacting to antigens of the H-2b haplotype reveal genetic control of isotype expression. J Immunol. 1981; 126(1):317-21. View

12.

Wilde D, Marrack P, Kappler J, Dialynas D, Fitch F . Evidence implicating L3T4 in class II MHC antigen reactivity; monoclonal antibody GK1.5 (anti-L3T4a) blocks class II MHC antigen-specific proliferation, release of lymphokines, and binding by cloned murine helper T lymphocyte lines. J Immunol. 1983; 131(5):2178-83. View

13.

Jacobson S, Sekaly R, Jacobson C, McFarland H, Long E . HLA class II-restricted presentation of cytoplasmic measles virus antigens to cytotoxic T cells. J Virol. 1989; 63(4):1756-62. PMC: 248439. DOI: 10.1128/JVI.63.4.1756-1762.1989. View

14.

Mueller D, Jenkins M, Schwartz R . Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu Rev Immunol. 1989; 7:445-80. DOI: 10.1146/annurev.iy.07.040189.002305. View

15.

Nuchtern J, Biddison W, Klausner R . Class II MHC molecules can use the endogenous pathway of antigen presentation. Nature. 1990; 343(6253):74-6. DOI: 10.1038/343074a0. View

16.

Ostrand-Rosenberg S, Thakur A, Clements V . Rejection of mouse sarcoma cells after transfection of MHC class II genes. J Immunol. 1990; 144(10):4068-71. View

17.

Jaraquemada D, Marti M, Long E . An endogenous processing pathway in vaccinia virus-infected cells for presentation of cytoplasmic antigens to class II-restricted T cells. J Exp Med. 1990; 172(3):947-54. PMC: 2188531. DOI: 10.1084/jem.172.3.947. View

18.

Ostrand-Rosenberg S, Roby C, Clements V . Abrogation of tumorigenicity by MHC class II antigen expression requires the cytoplasmic domain of the class II molecule. J Immunol. 1991; 147(7):2419-22. View

19.

Golumbek P, Lazenby A, Levitsky H, Jaffee L, Karasuyama H, Baker M . Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science. 1991; 254(5032):713-6. DOI: 10.1126/science.1948050. View

20.

Liu Y, Janeway Jr C . Cells that present both specific ligand and costimulatory activity are the most efficient inducers of clonal expansion of normal CD4 T cells. Proc Natl Acad Sci U S A. 1992; 89(9):3845-9. PMC: 525587. DOI: 10.1073/pnas.89.9.3845. View